Prostate-specific membrane antigen (PSMA) PET/CT shows high detection rates in clear-cell RCC, particularly in metastatic disease, with reported sensitivities of approximately 85-90% and management changes in up to 40-50% of selected cohorts. Here, FOLH1 is linked to metastatic neoplasm.